Inventor
BOYLAN JOHN FREDERICK
US12 patents
⚠️ This page may combine multiple inventors who share the name “BOYLAN JOHN FREDERICK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SIGNAL PHARM LLC
5 patentsUS9512124B2Dec 6, 2016
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC32 citations96
US9737541B2Aug 22, 2017
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC12 citations91
US10940152B2Mar 9, 2021
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10646493B2May 12, 2020
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US11590139B2Feb 28, 2023
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC0 citations61
ARROWHEAD PHARMACEUTICALS INC
3 patentsUS11920134B2Mar 5, 2024
Compositions and methods for inhibiting expression of RRM2 genes
ARROWHEAD PHARMACEUTICALS INC0 citations60
US10619160B2Apr 14, 2020
Compositions and methods for inhibiting expression of RRM2 genes
ARROWHEAD PHARMACEUTICALS INC0 citations49
US9938531B2Apr 10, 2018
Compositions and methods for inhibiting expression of RRM2 genes
ARROWHEAD PHARMACEUTICALS INC0 citations49
BOYLAN JOHN FREDERICK
3 patentsUS8946176B2Feb 3, 2015
Compositions and methods for inhibiting expression of RRM2 genes
BOYLAN JOHN FREDERICK1 citations58
US8741889B2Jun 3, 2014
Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
BOYLAN JOHN FREDERICK3 citations50
US8309299B2Nov 13, 2012
Combination therapy and method for assessing resistance to treatment
BOYLAN JOHN FREDERICK0 citations49